Compare
aTYR PHARMA INC vs VivoSim Labs, Inc. vs AIM ImmunoTech Inc. vs Cardiff Oncology, Inc.
| Latest fiscal year | aTYR PHARMA INC ATYR | VivoSim Labs, Inc. VIVS | AIM ImmunoTech Inc. AIM | Cardiff Oncology, Inc. CRDF |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $190.0K | $131.0K | $88.0K | $593.0K |
| Revenue growth (YoY) | -19.1% | -9.0% | -48.2% | -13.2% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$74.12M | -$13.84M | -$13.96M | -$45.85M |
| EPS (Diluted) | -$0.80 | -$5.35 | -$8.62 | -$0.69 |
| Operating cash flow | -$61.99M | -$10.83M | -$10.96M | -$37.92M |
| Free cash flow | -$62.06M | -$10.83M | n/a | -$37.97M |
| Cash & equivalents | $10.74M | $5.02M | $2.98M | $17.47M |
| Total assets | $93.00M | $7.39M | $5.78M | $61.88M |
| Total liabilities | n/a | $8.48M | $15.56M | $16.50M |
| Shareholders' equity | $67.48M | -$1.10M | -$9.78M | $45.39M |
| Return on year-end equity | -109.8% | n/a | n/a | -101.0% |
| Shares outstanding | 98.03M | 2.89M | 3.07M | 68.31M |
Revenue, most recent five fiscal years
| Fiscal year | aTYR PHARMA INC | VivoSim Labs, Inc. | AIM ImmunoTech Inc. | Cardiff Oncology, Inc. |
|---|---|---|---|---|
| Latest | $190.0K Ended 2025-12-31 | $131.0K Ended 2026-03-31 | $88.0K Ended 2025-12-31 | $593.0K Ended 2025-12-31 |
| 1 year earlier | $235.0K Ended 2024-12-31 | $144.0K Ended 2025-03-31 | $170.0K Ended 2024-12-31 | $683.0K Ended 2024-12-31 |
| 2 years earlier | $353.0K Ended 2023-12-31 | $109.0K Ended 2024-03-31 | $202.0K Ended 2023-12-31 | $488.0K Ended 2023-12-31 |
| 3 years earlier | $10.39M Ended 2022-12-31 | $370.0K Ended 2023-03-31 | $141.0K Ended 2022-12-31 | $386.0K Ended 2022-12-31 |
| 4 years earlier | $0 Ended 2021-12-31 | $1.50M Ended 2022-03-31 | $135.0K Ended 2021-12-31 | $359.0K Ended 2021-12-31 |